Filing Details
- Accession Number:
- 0000950170-25-054883
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-04-16 17:39:06
- Reporting Period:
- 2025-04-14
- Filing Date:
- 2025-04-16
- Accepted Time:
- 2025-04-16 17:39:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1877680 | Andrea Ellis | C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-04-14 | 10,000 | $8.45 | 22,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-04-14 | 10,000 | $35.00 | 12,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2025-04-14 | 10,000 | $0.00 | 10,000 | $8.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 64,921 | 2032-06-22 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.
- The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Billionaire Hedge Funds
